Firma Noxxon Pharma, Autor bei PR-Web

NOXXON annonce la convocation de l’assemblée générale annuelle des actionnaires 2022

Posted on 30. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, cancer, déclarations, est, euroclear, les, microsatellites, noxxon, optimus, pancréas, patients, radiothérapie, résection, une, vertu

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société de biotechnologie spécialisée dans le développement de traitements améliorés du cancer ciblant le microenvironnement tumoral (MET), annonce aujourd’hui la convocation de l’assemblée générale annuelle des actionnaires de la société (l’AG) le […]

NOXXON announces convocation of the 2022 annual general meeting of shareholder

Posted on 30. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, agm, brain, cancer, clinical, euroclear, nox, noxxon, optimus, patients, radiotherapy, report, spiegelmer, statements, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 02.00 p.m. […]

NOXXON annonce la présentation des données de phase 1/2 de NOX-A12 dans le glioblastome lors de la réunion annuelle 2022 de l’ASCO et l’organisation d’un événement dédié en présence de leaders d’opinion renommés

Posted on 27. May 2022 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, biopsy, cancer, d'escalade, déclarations, est, les, lésions, microsatellites, noxxon, olaptesed, patients, pegol, radiothérapie, une

Les données principales de l’étude d’escalade de dose phase 1/2 GLORIA évaluant NOX-A12 dans le cancer du cerveau seront présentées à la réunion annuelle 2022 de l’ASCO qui se tiendra le 5 juin 2022. Organisation d’un webinaire le 10 juin […]

NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event

Posted on 27. May 2022 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, asco, biopsy, brain, cancer, clinical, grade, nox, noxxon, olaptesed, optimus, patients, pegol, statements, with

Full top-line results from dose escalation of NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented at ASCO 2022 on June 5, 2022 Key Opinion Leader (KOL) webinar with lead investigator of the GLORIA trial Dr. Frank A. […]

NOXXON met à jour son accord de financement avec Atlas

Posted on 19. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, cancer, déclarations, est, growth, les, microsatellites, nox, noxxon, optimus, patients, prospectives, radiothérapie, résection, une

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société de biotechnologie spécialisée dans le développement de traitements améliorés du cancer ciblant le microenvironnement tumoral (MET), annonce aujourd’hui un troisième amendement de son accord avec Atlas Special Opportunities, LLC (ASO). Cet […]

NOXXON amends equity-linked facility with Atlas

Posted on 19. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, aso, atlas, bonds, brain, cancer, financial, market, nox, noxxon, optimus, patients, radiotherapy, statements, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the third amendment to its agreement with Atlas Special Opportunities, LLC (ASO) which increases and equilibrizes all […]

NOXXON presente les résultats de son assembleé générale extraordinaire

Posted on 17. May 202217. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, cancer, déclarations, est, growth, les, microsatellites, nox, noxxon, optimus, patients, produits, prospectives, radiothérapie, une

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société de biotechnologie spécialisée dans le développement de traitements améliorés du cancer ciblant le microenvironnement tumoral (MET), annonce aujourd’hui que l’Assemblée Générale Extraordinaire qui s’est tenue le lundi 16 mai 2022 dans […]

NOXXON announces results of the extraordinary general meeting of shareholders

Posted on 17. May 202217. May 2022 by Firma Noxxon Pharma Posted in General Tagged a12, brain, cancer, financial, gemcitabine, glioblastoma, irinotecan, nox, noxxon, optimus, patients, radiotherapy, statements, tumor, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the extraordinary general meeting of shareholders held on Monday, May 16, 2022 at the offices of […]

NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancer

Posted on 3. November 2021 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, brain, cancer, clinical, gemcitabine, irinotecan, market, merck, nox, noxxon, optimus, patients, statements, therapy, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that due to supply-chain issues affecting its drug-supply manufacturer, the start date of its two upcoming NOX-A12 clinical […]

NOXXON Pharma update on NOX-A12 clinical programs

Posted on 5. August 2021 by Firma Noxxon Pharma Posted in Research / Development Tagged a12, brain, cancer, clinical, gemcitabine, irinotecan, keytruda, merck, nox, noxxon, optimus, paclitaxel, patients, therapy, with

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided today an update on the clinical development and timelines of its lead asset NOX-A12. As NOX-A12 recently reported […]